During the study, participants will receive their assigned treatment for up to 28 weeks. The study will measure changes in the liver by looking at specific markers in the blood that show liver scarring and damage, such as the Enhanced Liver Fibrosis score and other substances that indicate how much scar tissue is forming in the liver. The study will also use a special ultrasound device that measures liver stiffness and fat content by sending gentle vibrations through the liver. Blood tests will check liver enzymes, which are proteins released when liver cells are damaged, and cholesterol levels. To understand effects on alcohol use, the study will measure a substance in the blood called phosphatidylethanol that indicates recent alcohol consumption, and participants will report their alcohol intake over time. The study will also carefully monitor any side effects that occur during treatment.

Participants in this study must be adults who have a history of drinking significant amounts of alcohol regularly for at least five years and who have evidence of liver damage based on blood test results. The study will compare how well the different medications work by measuring changes in liver health markers and alcohol use from the beginning to the end of the treatment period.

During the study, participants will receive either the liquid form of Essentiale (1800 mg), Essentiale capsules, or a placebo. The medication or placebo will be taken daily for 87 days. The liquid medication comes in stick packs containing 1.8g of the substance, while the capsules contain 300 mg each. All participants will continue their regular liver disease treatment throughout the study.

The study will monitor changes in liver disease symptoms such as tiredness, depression, stomach discomfort, sleep problems, loss of appetite, and nausea. The medications and placebos are designed to look, taste, and smell the same so that participants cannot tell which form they are receiving. This helps ensure that the study results are reliable and unbiased.

The purpose of the study is to see if simvastatin can significantly reduce liver fibrosis in patients with chronic liver disease due to alcohol. Participants will receive either simvastatin or a placebo and will be monitored over a period of 24 months. During this time, the health of their liver will be assessed through various methods, including liver biopsies, which involve taking a small sample of liver tissue to examine under a microscope. The study will also look at changes in liver stiffness, which can be measured using special imaging techniques, and other markers in the blood that indicate liver health.

Throughout the study, researchers will also explore other aspects of liver health, such as changes in the gut microbiome, which is the community of bacteria living in the intestines, and markers of inflammation in the body. The safety and any side effects of simvastatin will be closely monitored to ensure the well-being of participants. This trial is designed to provide valuable insights into whether simvastatin can be a beneficial treatment for reducing liver damage in patients with alcoholic liver disease.

The purpose of the study is to assess how well GSK4532990A works in reducing liver damage in adults with ALD. Participants will receive a single dose of the treatment through an injection under the skin. The study will monitor participants over a period to observe any changes in their liver condition and to ensure the treatment is safe and well-tolerated.

Throughout the study, participants will undergo various assessments to track their health and the impact of the treatment. These assessments will include regular check-ups and tests to measure liver function and overall health. The study aims to provide valuable information on the potential benefits of GSK4532990A for individuals with alcohol-related liver disease.